Diagnosis and management of prediabetes in the continuum of hyperglycemia - When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists

Endocrine Practice

Volumn 14, Issue 7, 2008, Pages 933-946

  Garber, Alan J ^a   Handelsman, Yehuda ^a   Einhorn, Daniel ^a   Bergman, Donald A ^a   Bloomgarden, Zachary T ^a   Fonseca, Vivian ^a   Garvey, W Timothy ^a   Gavin III, James R ^a   Grunberger, George ^a   Horton, Edward S ^a   Jellinger, Paul S ^a   Jones, Kenneth L ^a   Lebovitz, Harold ^a   Levy, Philip ^a   McGuire, Darren K ^a   Moghissi, Etie S ^a   Nesto, Richard W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIPID; METFORMIN; PLACEBO; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DRUG COST; ENDOCRINOLOGY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; MEDICAL SOCIETY; MONITORING; PRACTICE GUIDELINE; RISK FACTOR; WEIGHT REDUCTION; CONSENSUS DEVELOPMENT;

DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; PREDIABETIC STATE; RISK FACTORS;

EID: 63849238764     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.7.933     Document Type: Conference Paper

References (72)

1. Centers for Disease Control. Number of people with diabetes increases to 24 million. http://www.cdc.gov/media/ pressrel/2008/r080624.htm. Posted June 24, 2008. Accessed July 21, 2008.
2. Tapp RJ, Zimmet PZ, Harper CA, et al; AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract. 2006;73:315-321.
3. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies [erratum in Lancet. 2008;371:1838]. Lancet. 2008;371:736-743.
4. International Diabetes Federation. Diabetes Atlas: Prevalence. http://www.eatlas.idf.org/Prevalence/. Accessed August 1, 2008.
5. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 [erratum in Diabetes Care. 2008;31:1271]. Diabetes Care. 2008;31:596-615.
6. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
7. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066-3072.
8. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the Unites States, 2007. http://www. cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed July 30, 2008.
9. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
10. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, Gertein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial [erratum in Lancet. 2006;368:1770]. Lancet. 2006;368:1096-1105.
11. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783-1789.
12. Lindström J, Ilanne-Parikka P, Peltonen M, et al; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679.
13. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007; 334:299.
14. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494.
15. Ratner R, Goldberg R, Haffner S, et al; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888-894.
16. DREAM Trial Investigators, Dagenais GR, Gerstein HC, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial. Diabetes Care. 2008; 31:1007-1014.
17. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
18. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1): S12-S54.
19. Haffner S, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med. 2003;115(suppl 8A):6S-11S.
20. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008;51:264-270.
21. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007;24:137-144.
22. DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
23. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285:2109-2113.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
25. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151-157.
26. Muhlestein JB, Anderson JL, Horne BD, et al; Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351-358.
27. Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 2006;29:26-31.
28. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129-1134.
29. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care. 2007;30:332-336.
30. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM; San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26:3153-3159.
31. Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States [erratum in JAMA. 2007;298:627]. JAMA. 2007;297:2716-2724.
32. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
33. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care. 2008;31:1650-1655.
34. Bartnik M, Rydén L, Malmberg K, et al; Euro Heart Survey Investigators. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart. 2007;93:72-77.
35. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
36. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688-696.
37. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care. 2003;26:2910-2914.
38. Rodriguez BL, Lau N, Burchfiel CM, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care. 1999;22:1262-1265.
39. Carnethon MR, Prineas RJ, Temprosa M, et al; Diabetes Prevention Program Research Group. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006;29:914-919.
40. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist. 2008;14:23-29.
41. Ismail-Beigi F, Moghissi ES. Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocr Pract. 2008;14:639-643.
42. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
43. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
44. Abraira C, Duckworth WC. Veterans Affairs Diabetes Trial (VADT). Presented at: American Diabetes Association 68th Scientific Sessions; June 6-10, 2008; San Francisco, CA.
45. Orchard TJ, Temprosa M, Goldberg R, et al; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611-619.
46. Uusitupa M, Lindi V, Louheranta A, et al; Finnish Diabetes Prevention Study Group. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003;52: 2532-2538.
47. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
48. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321-1326.
49. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [erratum in Diabetes Care. 2004;27:856]. Diabetes Care. 2004;27:155-161.
50. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003;26:125-131.
51. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [erratum in Lancet. 2006;368:1650]. Lancet. 2006;368:1660-1672.
52. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet. 2007;370:1671-1672.
53. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
54. Knowler WC, Hamman RF, Edelstein SL, et al; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-1156.
55. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves betacell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008;31:108-113.
56. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30:2032-2033.
57. Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract. 2008;14:625-638.
58. Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based therapy for obese children. JAMA. 1990;264:2519-2523.
59. Rosenbaum M, Nonas C, Weil R, et al; El Camino Diabetes Prevention Group. School-based intervention acutely improves insulin sensitivity and decreases inflammatory markers and body fatness in junior high school students. J Clin Endocrinol Metab. 2007;92:504-508.
60. McCrindle BW, Urbina EM, Dennison BA, et al; American Heart Association, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948-1967.
61. Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198-208.
62. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25:476-481.
63. Herman WH, Hoerger TJ, Brandle M, et al; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323-332.
64. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251-264.
65. Ackermann RT, Marrero DG, Hicks KA, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care. 2006;29: 1237-1241.
66. Dalziel K, Segal L. Time to give nutrition interventions a higher profile: a cost-effectiveness of 10 nutrition interventions. Health Promot Int. 2007;22:271-283.
67. Palmer AJ, Roze S, Valentine WJ, Spinas G, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the longterm health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26:304-321.
68. Lindgren P, Lindström J, Tuomilehto J, et al; DPS Study Group. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care. 2007;23:177-183.
69. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: withintrial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30:2548-2552.
70. Diabetes Prevention Program Research Group. Withintrial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518-2523.
71. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006;12(suppl 1):25-30.
72. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29: 1130-1139.